Vir Biotechnology, Inc. (VIR) stock
VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3030% below fair value
$9.25−0.33 (-3.44%)
Close on Nov 17, 2026Market cap $1.57BP/E –Yield –
Vir Biotechnology pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Vir Biotechnology's pe ratio was 6.6× on Apr 28, 2023, against 5.1× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Apr 28, 2023 | 6.6× | +3.6 |
| 2022 | Dec 30, 2022 | 3.0× | – |
See a number that looks wrong?